cervical cancer
Conditions
Interventions
Local advanced cervical cancer:None
Sponsors
Shenzhen Hospital of Peking University
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-75 years; 2. Patients with histologically diagnosed cervical cancer (including squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, neuroendocrine carcinoma, undifferentiated carcinoma, etc.), endometrial cancer (endometrioid adenocarcinoma, endometrial serous carcinoma, clear cell carcinoma, carcinosarcoma, etc.), whose clinical stage is IB-IVA (FIGO 2018 stage); 3. According to RECIST 1.1 standard, there should be at least one measurable lesion; 4. No serious hematopoietic dysfunction, heart, lung, liver, kidney dysfunction, or immune deficiency; 5. ECOG score 0-2 points; 6. Expected survival time>=3 months; 7. Women with potential fertility are negative for serum or urine HCG within 72 hours before enrollment (postmenopausal women must have amenorrhea for at least 12 months to be considered infertile. For women who have been confirmed to have undergone tubal ligation surgery, pregnancy testing is not required); 8. Those without intrauterine devices; 9. Women with potential fertility are willing to use medically approved contraceptive measures during the experiment; 10. Good compliance, willing to sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Received previous pelvic radiation therapy, tumor targeted therapy and immunotherapy; 2. Patients with bilateral ureteral obstruction, unable to implant ureteral stents or perform pyelostomy; 3. Pregnant or lactating women; 4. Patients with rectovaginal fistula/vagino-bladder fistula/uncontrolled vaginal bleeding or at risk of fistula; 5. People infected with human immunodeficiency virus (HIV); 6. Active hepatitis B (HBV DNA quantitative test results exceed the lower limit), or HCV infection (HCV RNA quantitative test results exceed the lower limit); 7. Has a serious underlying medical condition that makes it impossible to safely administer the trial treatment. Including but not limited to active infections requiring systemic medication: compensatory heart failure (NYHA grade III and IV), unstable angina, and acute myocardial infarction within 3 months prior to enrollment; 8. Patients with a history of other malignant tumors (except cured basal cell carcinoma of the skin); 9. Patients with Crohn's disease and ulcerative colitis; 10. Are participating in other clinical trials or have stopped clinical trials for less than 4 weeks; 11. Patients with contraindications to cisplatin; 12. Neurological or psychiatric disorders that affect cognitive ability; 13. Patients whose lesions were evaluated by the investigator and who were unable to undergo endovascular radiation therapy; 14. There are other reasons not suitable for participating in this study as judged by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Abundance of bacteria;Treatment efficacy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Gastrointestinal reaction after concurrent chemoradiotherapy; | — |
Contacts
Public ContactLei Zhang
Shenzhen Hospital, Peking University
Outcome results
None listed